Matilde Risti

Dr. Matilde Risti

European Institute of Oncology, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Representative Publications

View All Publications
27 February 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
Matilde RistiMatilde Risti
Matilde Risti
MBMaria da Graça Bicalho
Maria da Graça Bicalho
This paper aims to present an overview of MICA and NKG2D genetic and functional interactions and their impact on kidney transplant outcome. Organ transplantation has gone from what can accurately be called a ‘‘clinical experiment’’ to a routine and reliable practice, which has proven to be clinically relevant, life-saving and cost effective when compared with non-transplantation management strategies of both chronic and acute end stage organ failures. The kidney is the most frequently transplanted organ in the world (transplant-observatory). The two treatment options for end-stage renal disease (ESRD) are dialysis and/or transplantation. Compared with dialysis, transplantation is associated with significant improvements in quality of life and overall longevity. A strong relationship exists between allograft loss and Human Leukocyte Antigens (HLA) antibodies. HLA antibodies are not the only factor involved in graft loss, as multiple studies have shown that non-HLA antigens are also involved, even when a patient has a good HLA matche and receives standard immunosuppressive therapy. A deeper understanding of other biomarkers is therefore important, as it is likely to lead to better monitoring (and consequent success) of organ transplants. The objective is to fill the void left by extensive reviews that don’t often dive this deep into the importance of MICA and NKG2D in allograft acceptance and their partnership in the immune response. There are few papers that explore the relationship between these two protagonists when it comes to kidney transplantation. This is especially true for the role of NKG2D in kidney transplantation. These reasons give a special importance to this review, which aims to be a helpful tool in the hands of researchers in this field.

22 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VHVanessa Hauer
Vanessa Hauer
Matilde RistiMatilde Risti
Matilde Risti
BMBruna L. M. Miranda
Bruna L. M. Miranda
JSJosé S. da Silva
José S. da Silva
ACAna L. Cidral
Ana L. Cidral
MBMaria da G. Bicalho
Maria da G. Bicalho
The HLA-G and MICA genes are stimulated under inflammatory conditions and code for soluble (sMICA and sHLA-G) or membrane-bound molecules that exhibit immunomodulatory properties. It is still unclear whether they would have a synergistic or antagonistic effect on the immunomodulation of the inflammatory response, such as in chronic kidney disease (CKD), contributing to a better prognosis after the kidney transplantation. In this study, we went from genetic to plasma analysis, first evaluating the polymorphism of MICA, NKG2D and HLA-G in a cohort from Southern Brazil, subdivided in a control group of individuals (n = 75), patients with CKD (n = 94), and kidney-transplant (KT) patients (n = 64). MICA, NKG2D and HLA-G genotyping was performed by polymerase chain reaction with specific oligonucleotide probes, Taqman and Sanger sequencing, respectively. Levels of soluble forms of MICA and HLA-G were measured in plasma with ELISA. Case-control analysis showed that the individuals with haplotype HLA-G*01:01/UTR-4 have a lower susceptibility to develop chronic kidney disease (OR = 0.480; p = 0.032). Concerning the group of kidney-transplant patients, the HLA-G genotypes +3010 GC (rs1710) and +3142 GC (rs1063320) were associated with higher risk for allograft rejection (OR = 5.357; p = 0.013 and OR = 5.357, p = 0.013, respectively). Nevertheless, the genotype +3010 GG (OR = 0.136; p = 0.041) was associated with kidney allograft acceptance, suggesting that it is a protection factor for rejection. In addition, the phenotypic analysis revealed higher levels of sHLA-G (p = 0.003) and sMICA (p < 0.001) in plasma were associated with the development of CKD. For patients who were already under chronic pathological stress and underwent a kidney transplant, a high sMICA (p = 0.001) in pre-transplant proved to favor immunomodulation and allograft acceptance. Even so, the association of genetic factors with differential levels of soluble molecules were not evidenced, we displayed a synergistic effect of sMICA and sHLA-G in response to inflammation. This increase was observed in CKD patients, that when undergo transplantation, had this previous amount of immunoregulatory molecules as a positive factor for the allograft acceptance.

13 January 2025 in Genes
Verified
Journal Article
Open access
PDF file
EMEliza Del Fiol Manna
Eliza Del Fiol Manna
DSDavide Serrano
Davide Serrano
LCLaura Cazzaniga
Laura Cazzaniga
SMSara Mannucci
Sara Mannucci
CZCristina Zanzottera
Cristina Zanzottera
Matteo LazzeroniMatteo Lazzeroni
Matteo Lazzeroni
Women carrying pathogenic/likely pathogenic (P/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P/LP variants associated with breast cancer risk show incomplete penetrance. Age, gender, family history, polygenic risk, lifestyle, reproductive, hormonal, and environmental factors can affect the expressivity and penetrance of the disease. However, there are gaps in translating how individual genomic variation affects phenotypic presentation. The expansion of criteria for genetic testing and the increasing utilization of comprehensive genetic panels may enhance the identification of individuals carrying P/LP variants linked to hereditary breast cancer. Individualized risk assessment could facilitate the implementation of personalized risk-reduction strategies for these individuals. Preventive interventions encompass lifestyle modifications, chemoprevention, enhanced surveillance through breast imaging, and risk-reducing surgeries. This review addresses the current literature’s inconsistencies and limitations, particularly regarding risk factors and the intensity of preventive strategies for women with P/LP variants in moderate- and high-penetrance genes. In addition, it synthesizes the latest evidence on risk assessment and primary and secondary prevention in women at high risk of breast cancer.

18 July 2023 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
GCGiovanni Corso
Giovanni Corso
MMMonica Marabelli
Monica Marabelli
MCMariarosaria Calvello
Mariarosaria Calvello
SGSara Gandini
Sara Gandini
Matilde RistiMatilde Risti
Matilde Risti
BBBernardo Bonanni
Bernardo Bonanni

20 January 2025 in Tumori Journal
Verified
Journal Article
Open access
LCLaura Cazzaniga
Laura Cazzaniga
CZCristina Zanzottera
Cristina Zanzottera
SMSara Mannucci
Sara Mannucci
FFFrancesca Fava
Francesca Fava
MMMonica Marabelli
Monica Marabelli
BBBernardo Bonanni
Bernardo Bonanni
Lynch syndrome is a genetic condition predisposing to cancer, particularly colorectal cancer and endometrial cancer, due to germline mutations in MisMatch Repair genes. More rarely, Lynch syndrome is the result of a constitutional MLH1 promoter methylation. This review summarizes the current knowledge about the role of this epigenetic mechanism in the Lynch syndrome. Universal Tumor Screening, performed on tumoral specimens to identify features suggestive of Lynch syndrome, shows the same features both in the case of sporadic cancers and Lynch syndrome-cancers due to a constitutional MLH1 methylation: microsatellite instability, deficiency of MisMatch Repair proteins, and methylation of MLH1 gene. Over the last few years, identifying methylation of MLH1 promoter on tumors was used to discern sporadic tumors from Lynch syndrome tumors: the methylation of the MLH1 promoter was usually explained as a somatic event and this could lead to a missed diagnosis of some Lynch syndrome cases. Therefore, establishing criteria to decide when to test patients for constitutional MLH1 methylation is urgent. In the case of microsatellite instability/deficiency of MisMatch Repair tumors with MLH1 methylation, a germline genetic test could be requested for all colorectal cancer patients aged 55 years or younger and all endometrial cancer patients younger than 50 years old, independently from family history. The prevalence of germline MLH1 epimutations is not precisely known and possibly underestimated. The associated cancer risk could be similar to that due to a MLH1 sequence variant. MLH1 epimutations could be secondary to other genetic defects and follow an autosomal dominant inheritance. On the contrary, primary epimutations are often “ de novo” events, and their transmission does not follow Mendelian rules.

29 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EMEliza Del Fiol Manna
Eliza Del Fiol Manna
DSDavide Serrano
Davide Serrano
LCLaura Cazzaniga
Laura Cazzaniga
SMSara Mannucci
Sara Mannucci
CZCristina Zanzottera
Cristina Zanzottera
Matteo LazzeroniMatteo Lazzeroni
Matteo Lazzeroni
Women carrying pathogenic/likely pathogenic (P/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P/LP variants associated with breast cancer risk show incomplete penetrance. Age, gender, family history, polygenic risk, lifestyle, reproductive, hormonal, and environmental factors can affect the expressivity and penetrance of the disease. However, there are gaps in translating how individual genomic variation affects phenotypic presentation. The expansion of criteria for genetic testing and the increasing utilization of comprehensive genetic panels may enhance the identification of individuals carrying P/LP variants linked to hereditary breast cancer. Individualized risk assessment could facilitate the implementation of personalized risk-reduction strategies for these individuals. Preventive interventions encompass lifestyle modifications, chemoprevention, enhanced surveillance through breast imaging, and risk-reducing surgeries. This review addresses the current literature's inconsistencies and limitations, particularly regarding risk factors and the intensity of preventive strategies for women with P/LP variants in moderate- and high-penetrance genes. In addition, it synthesizes the latest evidence on risk assessment and primary and secondary prevention in women at high risk of breast cancer.